Chromosome 3P Loss of Heterozygosity and Mutation Analysis of the FHIT and Â-Cat Genes in J Clin Pathol: First Published As 10.1136/Jcp.51.7.520 on 1 July 1998

Total Page:16

File Type:pdf, Size:1020Kb

Chromosome 3P Loss of Heterozygosity and Mutation Analysis of the FHIT and Â-Cat Genes in J Clin Pathol: First Published As 10.1136/Jcp.51.7.520 on 1 July 1998 520 J Clin Pathol 1998;51:520–524 Chromosome 3p loss of heterozygosity and mutation analysis of the FHIT and â-cat genes in J Clin Pathol: first published as 10.1136/jcp.51.7.520 on 1 July 1998. Downloaded from squamous cell carcinoma of the head and neck María Victoria González, Marta F Pello, Pilar Ablanedo, Carlos Suárez, Victoria Alvarez, Eliecer Coto Abstract HNSCC is strongly associated with tobacco Aims—To study the loss of heterozygosity and alcohol consumption.3 at the short arm of chromosome 3 in pri- Several genetic alterations have been de- mary tumours from patients with scribed in tumours from HNSCC patients, squamous cell carcinoma of the head and including non-random cytogenetic abnormali- neck; to determine whether the FHIT ties, mutations or overexpression of the H-ras, gene, mapped to 3p14.2 and the CTNNB1 p53, and cyclin D genes, and alterations of the (â-cat) gene, mapped to 3p21, are deleted p16INK4A gene.4–8 Increased expression of epi- or mutated in these tumours. dermal growth factor receptor and mutations Methods—DNA was extracted from fresh at several oncogenes have also been tumours. Loss of heterozygosity was as- reported.910 sessed by microsatellite analysis of the Functional loss of tumour suppressor genes following markers: D3S1283 and D3S1286 is one of the most common genetic alterations (3p24), D3S966 (3p21), and D3S1300 in human neoplasms. Defining chromosomal (3P14.2). Homozygous deletion was deter- regions that harbour biologically important mined by radioactive multiplex polymer- tumour suppressor genes may have practical ase chain reaction of exons 5 and 6 of the implications for the diagnosis and management FHIT gene. The presence of mutations in of these tumours. Cytogenetic studies have FHIT exon 5 and â-cat exon 3 was studied revealed that the short arm of chromosome 3 is by single strand conformation polymor- often altered by chromosomal rearrangements phism. and deletions in several cancer types, including Results—50% of informative cases (25/50) HNSCC.41112These data suggest the presence showed loss of heterozygosity for at least of one or more tumour suppressor genes one of the 3p markers. 3p21 was the region located at 3p, inactivation of which may http://jcp.bmj.com/ with the highest rate of allelic deletion contribute to HNSCC development. Three (63%). No point mutation was found in commonly deleted regions, mapped to 3p24- FHIT exon 5 or â-cat exon 3. No case ter, 3p21.3, and 3p14-cen, have recently been showed homozygous deletion for the FHIT identified by analysis of allelic losses (loss of (exons 5 and 6) or the â-cat exon 3. heterozygosity).13–15 Conclusions—The short arm of chromo- Homozygous deletions are detected at a some 3 is often deleted in the head and much lower frequency than heterozygous dele- neck squamous cell carcinomas. In the on September 27, 2021 by guest. Protected copyright. tions and are usually smaller in size. Therefore remaining alleles of the FHIT or â-cat homozygous deletions may be of considerable genes, no evidence was found for point help in the localisation and identification of mutations or deletions, documented in tumour suppressor genes. A 440 kb ho- other common carcinomas. Inactivation mozygous deletion mapped to the distal part of Hospital Central de could occur by diVerent mechanisms such Asturias, Oviedo, as methylation, or other genes (not stud- 3p21 has been described in a small cell lung Spain ied here) could be target of allelic losses in carcinoma cell line, where a tumour suppressor Laboratorio de gene locus has been proposed.16 17 Genética Molecular squamous cell carcinoma of the head and neck. Recently, the fragile histidine triad gene M V González (FHIT) has been mapped to 3p14.2 and V Alvarez (J Clin Pathol 1998;51:520–524) E Coto shown to span a renal carcinoma associated 18 Keywords: squamous cell carcinoma of head and neck; translocation breakpoint. Altered transcripts Servicio de loss of heterozygosity; mutation analysis; FHIT gene; of FHIT were reported in about 80% of cases Otorrinolaringología â-cat gene of small cell lung carcinoma.19 The â-catenin M F Pello gene (CTNNB1) is located at chromosome C Suárez region 3p22-p21.3, where loss of heterozygos- Servicio de Patología Head and neck squamous cell carcinoma ity and homozygous deletion have been P Ablanedo (HNSCC) is one of the most common types of observed.20–22 The â-cat protein binds to cancer in the world. In Western countries it E-cadherin and á-catenin, thus being an essen- Correspondence to: 12 tial component of the cell–cell adhesion Dr Eliecer Coto, Servicio de accounts for up to 5% of all cancers. Despite Inmunología, Hospital eVorts to improve early diagnosis and treat- complex, also critical for intracellular signalling Central de Asturias, 33006 ment of patients with these neoplasms, their pathways.23 24 Downregulation of â-catenin Oviedo, Spain. prognosis remains poor. Its five year survival expression is associated with malignant 25 Accepted for publication rate has not changed in recent years, and is still transformation. â-Catenin has recently been 30 March 1998 one of the lowest among the prevalent cancers. shown to act as an oncoprotein in melanoma Chromosome 3p loss in squamous cell carcinoma of head and neck 521 Telomere moderately diVerentiated, and 11 were poorly diVerentiated tumours. With reference to J Clin Pathol: first published as 10.1136/jcp.51.7.520 on 1 July 1998. Downloaded from tumour stage, two neoplasms were stage I, seven were stage II, 18 were stage III, and 28 were stage IV. D3S1286 3p24.2 D3S1283 FHIT MICROSATELLITE LOSS OF HETEROZYGOSITY exons ANALYSIS Microsatellite markers D3S1286 and 10 D3S1283 (3p24.2), D3S966 (3p21.3), and D3S966 3p21.3 D3S1300 (3p14.2) were analysed to determine the loss of heterozygosity at the short arm of 6 chromosome 3. D3S1300 maps intragenic to D3S1300 the FHIT gene. Figure 1 represents the relative D3S1300 3p14.2 position of these markers. Primers were 5 previously described and are summarised in table 1.13 31 32 Polymerase chain reaction (PCR) was performed in a 15 µl reaction volume con- taining 100 ng genomic DNA, 10 pmol of each 1 primer, 200 µM each of dATP, dGTP, and dTTP, 100 µM dCTP, 2 mM MgCl2, 0.10 µCi [á-32P]dCTP (3000 Ci/mmol, Amersham International, Amersham, Buckinghamshire, Centromere UK), 1 × Ta q buVer, and 0.5 units of Taq-DNA Figure 1 Chromosome 3p map indicating the position of the microsatellite markers used polymerase (Promega, Madison, Wisconsin, (D3S1286, D3S1283, D3S966, D3S1300) and the FHIT gene (filled and empty boxes USA). Conditions consisted of an initial dena- represent coding and non-coding exons, respectively). turing step of five minutes at 98°C, followed by ° and colon cancer cell lines. Small deletions and 25 cycles of 30 seconds at 98 C, one minute at ° ° point mutations aVecting Ser residues on its 58 C, and 20 seconds at 72 C, followed by a 26–28 final extension of five minutes at 75°C. NH2-terminal domain have been described. In this report we investigated loss of hetero- Taq-DNA polymerase was added after the ini- zygosity at several 3p regions in various tial denaturing step. PCR products were mixed HNSCC tumours. In addition, we searched for with one volume of denaturing loading buVer homozygous deletions and mutations at the (95% formamide, 1% xylene cyanol), heated at ° FHIT and â-cat genes. 98 C for five minutes, and electrophoresed on a 6% denaturing polyacrilamide gel (45% urea, 5.7% acrylamide, and 0.3% bis-acrylamide). Methods After electrophoresis the gels were vacuum http://jcp.bmj.com/ PATIENTS AND DNA EXTRACTION dried and autoradiographed at −80°C for 2–24 Paired tumour and blood samples from 55 hours. HNSCC patients were collected. The fresh After densitometric analysis of bands of the tumour tissue was isolated by microdissection, two matched samples, loss of heterozygosity and specimens containing more than 70% was defined as a reduction of at least 75% in neoplastic cells were placed at 37°C for 24 the signal of one allele in tumour DNA. hours in lysis solution containing sodium on September 27, 2021 by guest. Protected copyright. dodecyl sulphate (SDS) and proteinase K. PCR AMPLIFICATION OF THE FHIT, â-CAT, AND DNA was obtained after phenol-chloroform DD1 LOCI extraction and ethanol precipitation.29 DNA Genomic DNA from primary tumours was from leucocytes was obtained according to a simultaneously amplified for exons 5 and 6 of previously described protocol.30 the FHIT gene by multiplex PCR (the sets of The 55 samples were from the pharynx (22), primers for both loci were included in the PCR larynx (30), and floor of the mouth (3). Histo- reaction mixture) under the same conditions as logically, 27 were well diVerentiated, 17 were described for microsatellite analysis. A se- quence mapped to 3p21, designated DD1, was Table 1 Oligonucleotide sequence of microsatellite markers used also amplified, as well as exon 3 of the â-cat Marker Region Oligonucleotide sequence Size† Tm gene. PCR primers for these sequences were ° previously described and are summarised in D3S1286 3p24.2 Fwd GCAGTGACTTCAGAGGGGC 120 bp 58 C 33 34 Rvs ATTGACGGGGCTAGGGC table 1. One microlitre of formamide was D3S1283 3p24.2 Fwd GGCAGTACCACCTGTAGAAATG 120 bp 58°C also added to the PCR reaction mixtures to Rvs GAGTAACAGAGGCATCGTGTAT improve PCR specificity. We also reduced the D3S966 3p21.3 Fwd TACCTCCTCACTGTTTCATATTAG 120 bp 58°C Rvs CACATAGTATGTCTCGGCTAACAG number of PCR cycles to 25 in order to mini- D3S1300 3p14.2 Fwd AGCTCACATTCTAGTCAGCCT 220 bp 57°C mise the masking eVect of “contaminant” Rvs GCCAATTCCCCAGATG Exon 5 FHIT 3p14.2 Fwd TCAACTGTGAGGACATGTCG 140 bp 58°C DNA from non-tumour cells.
Recommended publications
  • Whole-Genome Microarray Detects Deletions and Loss of Heterozygosity of Chromosome 3 Occurring Exclusively in Metastasizing Uveal Melanoma
    Anatomy and Pathology Whole-Genome Microarray Detects Deletions and Loss of Heterozygosity of Chromosome 3 Occurring Exclusively in Metastasizing Uveal Melanoma Sarah L. Lake,1 Sarah E. Coupland,1 Azzam F. G. Taktak,2 and Bertil E. Damato3 PURPOSE. To detect deletions and loss of heterozygosity of disease is fatal in 92% of patients within 2 years of diagnosis. chromosome 3 in a rare subset of fatal, disomy 3 uveal mela- Clinical and histopathologic risk factors for UM metastasis noma (UM), undetectable by fluorescence in situ hybridization include large basal tumor diameter (LBD), ciliary body involve- (FISH). ment, epithelioid cytomorphology, extracellular matrix peri- ϩ ETHODS odic acid-Schiff-positive (PAS ) loops, and high mitotic M . Multiplex ligation-dependent probe amplification 3,4 5 (MLPA) with the P027 UM assay was performed on formalin- count. Prescher et al. showed that a nonrandom genetic fixed, paraffin-embedded (FFPE) whole tumor sections from 19 change, monosomy 3, correlates strongly with metastatic death, and the correlation has since been confirmed by several disomy 3 metastasizing UMs. Whole-genome microarray analy- 3,6–10 ses using a single-nucleotide polymorphism microarray (aSNP) groups. Consequently, fluorescence in situ hybridization were performed on frozen tissue samples from four fatal dis- (FISH) detection of chromosome 3 using a centromeric probe omy 3 metastasizing UMs and three disomy 3 tumors with Ͼ5 became routine practice for UM prognostication; however, 5% years’ metastasis-free survival. to 20% of disomy 3 UM patients unexpectedly develop metas- tases.11 Attempts have therefore been made to identify the RESULTS. Two metastasizing UMs that had been classified as minimal region(s) of deletion on chromosome 3.12–15 Despite disomy 3 by FISH analysis of a small tumor sample were found these studies, little progress has been made in defining the key on MLPA analysis to show monosomy 3.
    [Show full text]
  • Evaluation of the FHIT Gene in Colorectal Cancers1
    [CANCER RESEARCH 56, 2936-2939. July I. 1996] Advances in Brief Evaluation of the FHIT Gene in Colorectal Cancers1 Sam Thiagalingam, Nikolai A. Lisitsyn, Masaaki Hamaguchi, Michael H. Wigler, James K. V. Willson, Sanford D. Markowitz, Frederick S. Leach, Kenneth W. Kinzler, and Bert Vogelstein2 The Johns Hopkins Oncology Center. Baltimore, Maryland 21231 [S. T.. F. S. L., K. W. K., B. V.]; Department of Genetics. University of Pennsylvania, Philadelphia, Pennsylvania 9094 ¡N.A. LI: Cold Spring Harbor Laboratory, Cold Spring Harbor, New York 11724 ¡M.H., M. H. W.]; Department of Medicine and Ireland Cancer Center, University Hospitals of Cleveland and Case Western Resene University. Cleveland. Ohio 44106 ¡J.K. V. W., and S. D. M.¡; and Howard Hughes Medical Institute [B. V.¡,The Johns Hopkins Oncology Center, Baltimore, Maryland 21231 Abstract suppressor genes (13), the RDA results strongly supported the exist ence of a tumor suppressor gene in this area (14). A variety of studies suggests that tumor suppressor loci on chromosome Finally, Ohta et al. (15) have recently used a positional cloning 3p are important in various forms of human neoplasia. Recently, a chro approach to identify a novel gene that spanned the t(3;8) breakpoint. mosome 3pl4.2 gene called FHIT was discovered and proposed as a They named this gene FHIT (fragile histidine triad gene), reflecting its candidate tumor suppressor gene in coloréela!and other cancers. We evaluated the FHIT gene in a panel of colorectal cancer cell lines and homology to the Schizosaccharomyces pombe gene encoding Ap4A xenografts, which allowed a comprehensive mutational analysis.
    [Show full text]
  • Initial Sequencing and Comparative Analysis of the Mouse Genome
    articles Initial sequencing and comparative analysis of the mouse genome Mouse Genome Sequencing Consortium* *A list of authors and their af®liations appears at the end of the paper ........................................................................................................................................................................................................................... The sequence of the mouse genome is a key informational tool for understanding the contents of the human genome and a key experimental tool for biomedical research. Here, we report the results of an international collaboration to produce a high-quality draft sequence of the mouse genome. We also present an initial comparative analysis of the mouse and human genomes, describing some of the insights that can be gleaned from the two sequences. We discuss topics including the analysis of the evolutionary forces shaping the size, structure and sequence of the genomes; the conservation of large-scale synteny across most of the genomes; the much lower extent of sequence orthology covering less than half of the genomes; the proportions of the genomes under selection; the number of protein-coding genes; the expansion of gene families related to reproduction and immunity; the evolution of proteins; and the identi®cation of intraspecies polymorphism. With the complete sequence of the human genome nearly in hand1,2, covering about 90% of the euchromatic human genome, with about the next challenge is to extract the extraordinary trove of infor- 35% in ®nished form1. Since then, progress towards a complete mation encoded within its roughly 3 billion nucleotides. This human sequence has proceeded swiftly, with approximately 98% of information includes the blueprints for all RNAs and proteins, the genome now available in draft form and about 95% in ®nished the regulatory elements that ensure proper expression of all genes, form.
    [Show full text]
  • Anti-FHIT Antibody (ARG58030)
    Product datasheet [email protected] ARG58030 Package: 50 μg anti-FHIT antibody Store at: -20°C Summary Product Description Rabbit Polyclonal antibody recognizes FHIT Tested Reactivity Hu Tested Application FACS, ICC/IF, IHC-P, WB Host Rabbit Clonality Polyclonal Isotype IgG Target Name FHIT Species Human Immunogen Recombinant protein corresponding to aa. 1-147 of Human FHIT. Conjugation Un-conjugated Alternate Names FRA3B; AP3Aase; Bis(5'-adenosyl)-triphosphatase; EC 3.6.1.29; AP3A hydrolase; AP3Aase; Diadenosine 5',5'''-P1,P3-triphosphate hydrolase; Dinucleosidetriphosphatase; Fragile histidine triad protein Application Instructions Application table Application Dilution FACS 1 - 3 µg/10^6 cells ICC/IF 1 - 5 µg/ml IHC-P 1 - 5 µg/ml WB 0.5 - 1 µg/ml Application Note * The dilutions indicate recommended starting dilutions and the optimal dilutions or concentrations should be determined by the scientist. Observed Size ~ 17 kDa Properties Form Liquid Purification Affinity purification with immunogen. Buffer PBS, 0.025% Sodium azide and 2.5% BSA. Preservative 0.025% Sodium azide Stabilizer 2.5% BSA Concentration 0.5 mg/ml Storage instruction For continuous use, store undiluted antibody at 2-8°C for up to a week. For long-term storage, aliquot and store at -20°C or below. Storage in frost free freezers is not recommended. Avoid repeated www.arigobio.com 1/3 freeze/thaw cycles. Suggest spin the vial prior to opening. The antibody solution should be gently mixed before use. Note For laboratory research only, not for drug, diagnostic or other use. Bioinformation Gene Symbol FHIT Gene Full Name fragile histidine triad Background This gene, a member of the histidine triad gene family, encodes a diadenosine 5',5'''-P1,P3-triphosphate hydrolase involved in purine metabolism.
    [Show full text]
  • Anti-FHIT Antibody (ARG58006)
    Product datasheet [email protected] ARG58006 Package: 50 μg anti-FHIT antibody Store at: -20°C Summary Product Description Rabbit Polyclonal antibody recognizes FHIT Tested Reactivity Hu Predict Reactivity Ms Tested Application ICC/IF, WB Host Rabbit Clonality Polyclonal Isotype IgG Target Name FHIT Antigen Species Human Immunogen Synthetic peptide corresponding to 18 aa (C-terminus) of Human FHIT. Conjugation Un-conjugated Alternate Names FRA3B; AP3Aase; Bis(5'-adenosyl)-triphosphatase; EC 3.6.1.29; AP3A hydrolase; AP3Aase; Diadenosine 5',5'''-P1,P3-triphosphate hydrolase; Dinucleosidetriphosphatase; Fragile histidine triad protein Application Instructions Application table Application Dilution ICC/IF 5 µg/ml WB 1 - 2 µg/ml Application Note * The dilutions indicate recommended starting dilutions and the optimal dilutions or concentrations should be determined by the scientist. Positive Control WB: HeLa cell lysate. Calculated Mw 17 kDa Observed Size 15 kDa Properties Form Liquid Purification Affinity purification with immunogen. Buffer PBS and 0.02% Sodium azide. Preservative 0.02% Sodium azide Concentration 1 mg/ml Storage instruction For continuous use, store undiluted antibody at 2-8°C for up to a week. For long-term storage, aliquot and store at -20°C or below. Storage in frost free freezers is not recommended. Avoid repeated www.arigobio.com 1/2 freeze/thaw cycles. Suggest spin the vial prior to opening. The antibody solution should be gently mixed before use. Note For laboratory research only, not for drug, diagnostic or other use. Bioinformation Gene Symbol FHIT Gene Full Name fragile histidine triad Background This gene, a member of the histidine triad gene family, encodes a diadenosine 5',5'''-P1,P3-triphosphate hydrolase involved in purine metabolism.
    [Show full text]
  • FHIT Gene Alterations in Head and Neck Squamous Cell Carcinomas (Fragile Site/Ap3a Hydrolase/Chromosome 3Pl4.2) LAURA VIRGILIO*, MICHELE Shustert, SUSANNE M
    Proc. Natl. Acad. Sci. USA Vol. 93, pp. 9770-9775, September 1996 Medical Sciences This contribution is part of the special series of Inaugural Articles by members of the National Academy of Sciences elected on April 30, 1996. FHIT gene alterations in head and neck squamous cell carcinomas (fragile site/Ap3A hydrolase/chromosome 3pl4.2) LAURA VIRGILIO*, MICHELE SHUSTERt, SUSANNE M. GOLLINt, MARIA LuISA VERONESE*, MASATAKA OHTA*, KAY HUEBNER*, AND CARLO M. CROCE* *Kimmel Cancer Institute and Kimmel Cancer Center, Jefferson Medical College, Philadelphia, PA 19107; and tDepartment of Human Genetics, University of Pittsburgh Graduate School of Public Health and the University of Pittsburgh Cancer Institute, Pittsburgh, PA 15261 Contributed by Carlo M. Croce, July 18, 1996 ABSTRACT To determine whether the FHIT gene at 3p25. All three regions present a loss of heterozygosity in 3pl4.2 is altered in head and neck squamous cell carcinomas 45-50% of the cases both at the precancerous and cancerous (HNSCC), we examined 26 HNSCC cell lines for deletions stages, with the exception of 3p2l.3, that shows a lower within the FHIT locus by Southern analysis, for allelic losses incidence (30%) in dysplastic lesions (18). Furthermore, pa- of specific exons FHIT by fluorescence in situ hybridization tients with dysplastic lesions with LOH either of 9p or 3p are (FISH) and for integrity ofFHIT transcripts. Three cell lines at higher risk of developing tumors. exhibited homozygous deletions within the FHIT gene, 55% Recently, we have cloned the FHIT gene, at 3pl4.2, which (15/25) showed the presence ofaberrant transcripts, and 65% encompasses the FRA3B fragile site, is disrupted by the t(3;8) (13/20) showed the presence of multiple cell populations with chromosomal translocation observed in a family with renal cell losses of different portions of FHIT alleles by FISH of FHIT carcinoma, and spans a region commonly deleted in cancer cell genomic clones to interphase nuclei.
    [Show full text]
  • UBE2I (Ubc9) [GST-Tagged] E2 - SUMO Conjugating Enzyme
    UBE2I (Ubc9) [GST-tagged] E2 - SUMO Conjugating Enzyme Alternate Names: P18, SUMO-1 protein ligase, UBC9, Ubiquitin conjugating enzyme UbcE2A, Ubiquitin like protein SUMO-1 conjugating enzyme Cat. No. 62-0065-020 Quantity: 20 µg Lot. No. 1426 Storage: -70˚C FOR RESEARCH USE ONLY NOT FOR USE IN HUMANS CERTIFICATE OF ANALYSIS Page 1 of 2 Background Physical Characteristics The enzymes of the SUMOylation pathway Species: human Protein Sequence: play a pivotal role in a number of cellu- MSPILGYWKIKGLVQPTRLLLEYLEEKYEEH lar processes including nuclear transport, Source: E. coli expression LYERDEGDKWRNKKFELGLEFPNLPYYIDGD signal transduction, stress responses and VKLTQSMAIIRYIADKHNMLGGCPKER cell cycle progression. Covalent modifica- Quantity: 20 µg AEISMLEGAVLDIRYGVSRIAYSKDFETLKVD tion of proteins by small ubiquitin-related FLSKLPEMLKMFEDRLCHKTYLNGDHVTHP modifiers (SUMOs) may modulate their Concentration: 1 mg/ml DFMLYDALDVVLYMDPMCLDAFPKLVCFK stability and subcellular compartmen- KRIEAIPQIDKYLKSSKYIAWPLQGWQAT talisation. Three classes of enzymes are Formulation: 50 mM HEPES pH 7.5, FGGGDHPPKSDLEVLFQGPLGSMSGIALSR involved in the process of SUMOylation; 150 mM sodium chloride, 2 mM LAQERKAWRKDHPFGFVAVPTKNPDGTMN an activating enzyme (E1), conjugating dithiothreitol, 10% glycerol LMNWECAIPGKKGTPWEGGLFKLRMLFKD enzyme (E2) and protein ligases (E3s). DYPSSPPKCKFEPPLFHPNVYPSGTVCLSILEED UBE2I is a member of the E2 conjugating Molecular Weight: ~45 kDa KDWRPAITIKQILLGIQELLNEPNIQDPAQAEA enzyme family and cloning of the human YTIYCQNRVEYEKRVRAQAKKFAPS gene was first described by Wang et al. Purity: >98% by InstantBlue™ SDS-PAGE Tag (bold text): N-terminal glutathione-S-transferase (GST) (1996). The human UBE2I cDNA contains Protease cleavage site: PreScission™ (LEVLFQtGP) 7 exons sharing 56% and 100% identity Stability/Storage: 12 months at -70˚C; UBE2I (regular text): Start bold italics (amino acid resi- with the yeast and mouse homologues aliquot as required dues 1-158) Accession number: NP_003336 (Nacerddine et al., 2005; Shi et al., 2000; Wang et al., 1996).
    [Show full text]
  • FHIT Monoclonal Antibody (M08), Clone 1C5
    FHIT monoclonal antibody (M08), clone 1C5 Catalog # : H00002272-M08 規格 : [ 100 ug ] List All Specification Application Image Product Mouse monoclonal antibody raised against a partial recombinant FHIT. Western Blot (Recombinant protein) Description: Sandwich ELISA (Recombinant Immunogen: FHIT (AAH32336, 31 a.a. ~ 130 a.a) partial recombinant protein with protein) GST tag. MW of the GST tag alone is 26 KDa. Sequence: VVPGHVLVCPLRPVERFHDLRPDEVADLFQTTQRVGTVVEKHFHGTSL TFSMQDGPEAGQTVKHVHVHVLPRKAGDFHRNDSIYEELQKHDKEDFPA SWR Host: Mouse enlarge Reactivity: Human ELISA Isotype: IgG3 Kappa Quality Control Antibody Reactive Against Recombinant Protein. Testing: Western Blot detection against Immunogen (36.63 KDa) . Storage Buffer: In 1x PBS, pH 7.4 Storage Store at -20°C or lower. Aliquot to avoid repeated freezing and thawing. Instruction: MSDS: Download Datasheet: Download Applications Western Blot (Recombinant protein) Protocol Download Sandwich ELISA (Recombinant protein) Page 1 of 3 2016/5/20 Detection limit for recombinant GST tagged FHIT is approximately 1ng/ml as a capture antibody. Protocol Download ELISA Gene Information Entrez GeneID: 2272 GeneBank BC032336 Accession#: Protein AAH32336 Accession#: Gene Name: FHIT Gene Alias: AP3Aase,FRA3B Gene fragile histidine triad gene Description: Omim ID: 601153 Gene Ontology: Hyperlink Gene Summary: This gene, a member of the histidine triad gene family, encodes a diadenosine 5',5'''-P1,P3-triphosphate hydrolase involved in purine metabolism. The gene encompasses the common fragile site FRA3B on
    [Show full text]
  • Genome-Wide Analysis of Genetic Alterations in Barrett's
    Laboratory Investigation (2009) 89, 385–397 & 2009 USCAP, Inc All rights reserved 0023-6837/09 $32.00 Genome-wide analysis of genetic alterations in Barrett’s adenocarcinoma using single nucleotide polymorphism arrays Thorsten Wiech1,5, Elisabeth Nikolopoulos1,5, Roland Weis1, Rupert Langer2, Kilian Bartholome´3, Jens Timmer3, Axel K Walch4, Heinz Ho¨fler2 and Martin Werner1 We performed genome-wide analysis of copy-number changes and loss of heterozygosity (LOH) in Barrett’s esophageal adenocarcinoma by single nucleotide polymorphism (SNP) microarrays to identify associated genomic alterations. DNA from 27 esophageal adenocarcinomas and 14 matching normal tissues was subjected to SNP microarrays. The data were analyzed using dChipSNP software. Copy-number changes occurring in at least 25% of the cases and LOH occurring in at least 19% were regarded as relevant changes. As a validation, fluorescence in situ hybridization (FISH) of 8q24.21 (CMYC) and 8p23.1 (SOX7) was performed. Previously described genomic alterations in esophageal adenocarcinomas could be confirmed by SNP microarrays, such as amplification on 8q (CMYC, confirmed by FISH) and 20q13 or deletion/LOH on 3p (FHIT) and 9p (CDKN2A). Moreover, frequent gains were detected on 2p23.3, 7q11.22, 13q31.1, 14q32.31, 17q23.2 and 20q13.2 harboring several novel candidate genes. The highest copy numbers were seen on 8p23.1, the location of SOX7, which could be demonstrated to be involved in amplification by FISH. A nuclear overexpression of the transcription factor SOX7 could be detected by immunohistochemistry in two amplified tumors. Copy-number losses were seen on 18q21.32 and 20p11.21, harboring interesting candidate genes, such as CDH20 and CST4.
    [Show full text]
  • 5 Cpg Island Methylation of the FHIT Gene Is Correlated with Loss Of
    [CANCER RESEARCH 61, 3581–3585, May 1, 2001] Advances in Brief 5؅ CpG Island Methylation of the FHIT Gene Is Correlated with Loss of Gene Expression in Lung and Breast Cancer1 Sabine Zo¨chbauer-Mu¨ller, Kwun M. Fong, Anirban Maitra, Stephen Lam, Joseph Geradts, Raheela Ashfaq, Arvind K. Virmani, Sarah Milchgrub, Adi F. Gazdar, and John D. Minna2 Hamon Center for Therapeutic Oncology Research [S. Z-M., A. M., A. K. V., A. F. G., J. D. M.] and Departments of Pathology [A. M., R. A., S. M., A. F. G.], Internal Medicine [J. D. M.], and Pharmacology [J. D. M.], The University of Texas Southwestern Medical Center, Dallas, Texas 75390; Department of Thoracic Medicine, The Prince Charles Hospital, Brisbane 4032, Australia [K. M. F.]; British Columbia Cancer Agency, Vancouver V5Z 355, Canada [S. L.]; and Nuffield Department of Clinical Laboratory Sciences, University of Oxford, John Radcliffe Hospital, Oxford OX3 9DU, United Kingdom [J. G.] Abstract Aberrant methylation (referred to as methylation) of normally un- methylated CpG islands, located in the 5Ј promoter region of genes, Allele loss and loss of expression of fragile histidine triad (FHIT), a has been associated with transcriptional inactivation of several genes putative tumor suppressor gene located in chromosome region 3p14.2, are in human cancer and can serve as an alternative to mutational inac- frequent in several types of cancers. Tumor-acquired methylation of ␤ promoter region CpG islands is one method for silencing tumor suppres- tivation (12, 13). Several genes, including p16, RAR , TIMP-3, -sor genes. We investigated 5؅ CpG island methylation of the FHIT gene in DAPK, H-cadherin, and RASSF1A frequently undergo such methyl 107 primary non-small cell lung cancer (NSCLC) samples and corre- ation in lung and breast cancers (12, 14–23).
    [Show full text]
  • Chromosome 3P and Breast Cancer
    B.J Hum Jochimsen Genet et(2002) al.: Stetteria 47:453–459 hydrogenophila © Jpn Soc Hum Genet and Springer-Verlag4600/453 2002 MINIREVIEW Qifeng Yang · Goro Yoshimura · Ichiro Mori Takeo Sakurai · Kennichi Kakudo Chromosome 3p and breast cancer Received: April 30, 2002 / Accepted: May 27, 2002 Abstract Solid tumors in humans are now believed to are now believed to develop through a multistep process develop through a multistep process that activates that activates oncogenes and inactivates tumor suppressor oncogenes and inactivates tumor suppressor genes. Loss of genes (Lopez-Otin and Diamandis 1998). Inactivation of a heterozygosity at chromosomes 3p25, 3p22–24, 3p21.3, tumor suppressor gene (TSG) often involves mutation of 3p21.2–21.3, 3p14.2, 3p14.3, and 3p12 has been reported in one allele and loss or replacement of a chromosomal seg- breast cancers. Retinoid acid receptor 2 (3p24), thyroid ment containing another allele. Loss of heterozygosity hormone receptor 1 (3p24.3), Ras association domain fam- (LOH) has been found on chromosomes 1p, 1q, 3p, 6q, 7p, ily 1A (3p21.3), and the fragile histidine triad gene (3p14.2) 11q, 13q, 16q, 17p, 17q, 18p, 18q, and 22q in breast cancer have been considered as tumor suppressor genes (TSGs) for (Smith et al. 1993; Callahan et al. 1992; Sato et al. 1990; breast cancers. Epigenetic change may play an important Hirano et al. 2001a); the commonly deleted regions include role for the inactivation of these TSGs. Screens for pro- 3p, 6q, 7p, 11q, 16q, and 17p (Smith et al. 1993; Hirano et al. moter hypermethylation may be able to identify other TSGs 2001a).
    [Show full text]
  • High-Density Array Comparative Genomic Hybridization Detects Novel Copy Number Alterations in Gastric Adenocarcinoma
    ANTICANCER RESEARCH 34: 6405-6416 (2014) High-density Array Comparative Genomic Hybridization Detects Novel Copy Number Alterations in Gastric Adenocarcinoma ALINE DAMASCENO SEABRA1,2*, TAÍSSA MAÍRA THOMAZ ARAÚJO1,2*, FERNANDO AUGUSTO RODRIGUES MELLO JUNIOR1,2, DIEGO DI FELIPE ÁVILA ALCÂNTARA1,2, AMANDA PAIVA DE BARROS1,2, PAULO PIMENTEL DE ASSUMPÇÃO2, RAQUEL CARVALHO MONTENEGRO1,2, ADRIANA COSTA GUIMARÃES1,2, SAMIA DEMACHKI2, ROMMEL MARIO RODRÍGUEZ BURBANO1,2 and ANDRÉ SALIM KHAYAT1,2 1Human Cytogenetics Laboratory and 2Oncology Research Center, Federal University of Pará, Belém Pará, Brazil Abstract. Aim: To investigate frequent quantitative alterations gastric cancer is the second most frequent cancer in men and of intestinal-type gastric adenocarcinoma. Materials and the third in women (4). The state of Pará has a high Methods: We analyzed genome-wide DNA copy numbers of 22 incidence of gastric adenocarcinoma and this disease is a samples and using CytoScan® HD Array. Results: We identified public health problem, since mortality rates are above the 22 gene alterations that to the best of our knowledge have not Brazilian average (5). been described for gastric cancer, including of v-erb-b2 avian This tumor can be classified into two histological types, erythroblastic leukemia viral oncogene homolog 4 (ERBB4), intestinal and diffuse, according to Laurén (4, 6, 7). The SRY (sex determining region Y)-box 6 (SOX6), regulator of intestinal type predominates in high-risk areas, such as telomere elongation helicase 1 (RTEL1) and UDP- Brazil, and arises from precursor lesions, whereas the diffuse Gal:betaGlcNAc beta 1,4- galactosyltransferase, polypeptide 5 type has a similar distribution in high- and low-risk areas and (B4GALT5).
    [Show full text]